Generic Asthma Inhaler Launches in US Market
Patients managing asthma or COPD gain a bioequivalent option to a long-used maintenance inhaler.
Updated on Nov. 5, 2026 in Asthma

Live Poll
Would you notice lower prescription costs if more generic inhalers reached US pharmacies?
Aurobindo Pharma has launched gAdvair, a generic version of GSK's asthma and COPD inhaler Seretide, in the United States. The launch adds to the company's expanding respiratory and dermatology portfolio for patients and prescribers who rely on inhaled maintenance therapy.
Why it matters
Generic versions of branded inhalers can widen access to maintenance asthma and COPD treatment, where cost has historically been a barrier for many patients. The launch follows Cipla's delayed entry into the Advair market due to regulatory roadblocks, which kept the competitive field narrow.
These figures come from Aurobindo's own quarterly financial reporting rather than independent clinical or market review. The $900 million gAdvair opportunity and the $1.3 billion US dermatology market size are estimates, the latter attributed to IQVIA.
The players
Aurobindo Pharma
A Hyderabad-based generic drug manufacturer with a growing inhalation and dermatology pipeline, including the gAdvair and Atquey launches.
GSK
A global pharmaceutical company whose Seretide inhaler, the branded product behind gAdvair, is a major asthma and COPD maintenance therapy.
Otsuka Pharmaceutical
A Japanese drugmaker that licensed the dermatology product Atquey (difamilast) to Aurobindo.
IQVIA
A global health data and analytics firm whose estimate placed the US dermatology market at $1.3 billion.
The details
gAdvair is a bioequivalent of GSK's Seretide, a combination inhaler used for asthma and chronic obstructive pulmonary disease. Generic bioequivalents must deliver the same active ingredients at the same rate and extent as the branded product, which is what allows them to be approved and substituted at lower cost. Aurobindo also approved gQvar and entered the US dermatology segment with Atquey (difamilast), a product licensed from Japan's Otsuka Pharmaceutical. The company currently has four inhalation products in its in-house pipeline.
Timeline
Last month: Atquey launched in the US dermatology segment.
Over the next 12-18 months: Two more drugs are planned for launch, depending on loss-of-exclusivity timelines.
Over the coming quarters: The Pen-G facility is expected to turn EBITDA-positive, excluding PLI benefits.
Thursday: Aurobindo shares rose 4.4% on the NSE to Rs 1,781 apiece.
November 5, 2026: Post-results analyst call scheduled to address the gAdvair launch.
Health Landscape
Generic inhaled corticosteroid and bronchodilator combinations have been slower to reach the market than oral generics, largely because of the technical and regulatory complexity of demonstrating equivalence for inhaled devices. Each new entrant adds competition to a therapeutic area where branded maintenance inhalers have long dominated prescribing.
If you use a maintenance inhaler for asthma or COPD, a lower-cost generic may eventually become an option, but any change in your prescription should be discussed with your doctor or pharmacist. Patients should not switch inhalers on their own, since different devices have different techniques and dosing.
The takeaway
Generic entry into inhaler markets can broaden access to long-term asthma and COPD care, and expanding competition is a development worth following. If a generic inhaler is offered, ask your physician or pharmacist whether it is a suitable substitute for your current device.
What happens next
Aurobindo's post-results analyst call on November 5, 2026 is scheduled to address the gAdvair launch, and the company expects two more drug launches within 12-18 months.
Further reading
For background on how these inhalers are used to manage the condition, see our Asthma coverage.
Source note: This article includes information reported by ETPharma.
Live Poll
Would you notice lower prescription costs if more generic inhalers reached US pharmacies?


